Additionally, clinical trials of FGF21-based drugs, such as pegbelfermin, LLF580, and BIO89-100, have been performed on patients with NAFLD/NASH, and great effects have been observed. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.